Develops experimental medicines for people with severe autoimmune and inflammatory disorders, including gastrointestinal and inflammatory lung diseases.
10-K for FY2025, filed Mar 25, 2026We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to…View ↗
EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial…View ↗
EQ302 is a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery. Inhibiting…View ↗
We initially intend to develop EQ504 for the treatment of UC and other GI diseases with potential indication expansion opportunities for…View ↗
Ono paid for an exclusive option to acquire Equillium’s itolizumab rights and funded its development; Equillium had not established commercial sales or distribution capabilities.
10-K for FY2025, filed Mar 25, 2026
Pipeline focus
The older report described active clinical programs spanning peptide inhibitors and an antibody. The latest centers on preclinical therapies for gastrointestinal disease, with an AhR modulator as the main development priority.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to…View ↗
EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial…View ↗
EQ302 is a preclinical-stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery. Inhibiting…View ↗
EQ302 is a first-in-class, orally delivered, selective inhibitor of IL-15 and IL-21 and is both stable and permeable in the gut.View ↗
Partnership arrangements
The older report described Ono’s option and development funding for itolizumab alongside a Biocon license; the latest says Ono’s option expired and the Biocon agreements ended, and reports no product sales.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026On December 5, 2022, we entered into the Asset Purchase Agreement with Ono, pursuant to which we granted Ono the exclusive right, but not…View ↗
We are responsible for conducting all research and development of itolizumab (EQ001), which will be funded by Ono on a quarterly basis from…View ↗
We acquired the rights to itolizumab (EQ001) in May 2017, pursuant to a collaboration and license agreement with Biocon SA (subsequently…View ↗
Loading...